Bank of America Global Healthcare Conference
Logotype for Bruker Corporation

Bruker (BRKR) Bank of America Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Bruker Corporation

Bank of America Global Healthcare Conference summary

22 Sep, 2026

Financial performance and outlook

  • Organic order bookings and EPS outperformed in Q2, but revenue was delayed, with strong order growth in China and biopharma globally, while U.S. academic funding remained weak.

  • Semi-metrology business saw remarkable growth driven by AI demand and advanced packaging, with order strength across most geographies except U.S. academia.

  • High single-digit growth in diagnostics and strong performance in academic/government research outside the U.S.; Q3 expected push-outs in semi add to Q4 ramp.

  • Q4 2026 revenue expected to exceed €1 billion, with volume leverage and cost-saving actions supporting operating margin expansion.

  • 2027 outlook includes continued semi growth, biopharma recovery, and potential acceleration if industrial markets strengthen.

Market dynamics and funding environment

  • U.S. academic/government research funding is showing signs of improvement, but order conversion to revenue will likely benefit 2027 more than 2026.

  • Academic/government sector outside the U.S. (Europe, China, Korea, Japan) is performing well, with China showing stable and predictable funding.

  • China’s ability to quickly pivot and fund targeted sectors is a key growth driver, offsetting U.S. funding delays.

  • Biopharma and deep tech products are performing strongly in China and globally.

  • U.S. academic/government market now represents about 8% of total revenue, down from previous years.

Semi-metrology and product portfolio

  • Semi-metrology accounts for about 9% of revenue, with >15% order growth in Q2 and strong Q3 outlook; order conversion to revenue depends on customer fab timelines.

  • Backlog remains high, with order timing subject to customer needs, but cancellations are rare; smoother revenue curve expected by 2027.

  • Durable growth expected from flagship products like timsOmni (proteomics), timsMetabo (metabolites), and advanced microscopy and X-ray technologies.

  • Annual R&D investment supports continuous innovation and market leadership in key segments.

  • Expansion into energy fusion and security detection is expected to drive future growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more